HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
IR NEWS LETTER
Promethera announces Clinical Phase 2a of HepaStem at AASLD (11/11/2019)
- Promethera, a Belgian stem-cell medicine development company, announces the result of HepaStem’s Europe clinical phase 2a (aimed at patients with Acute-on-chronic liver failure (ACLF)) at American Associationfor the Study of Liver Diseases (AASLD) holding in Boston from November 8th to 12th.
- The following clinic was individually progressed by Promethera in Europe and evaluated the safety and efficacy of HepaStem.
- HepaStem is a liver-derived stem cell developed by Promethera and Lifeliver Inc. (an affiliated company of HLB Life Science) owns a domestic copyright.